Ozepic in Souss? The government earns certificates to include Liraglutide and Smaglutida | health
The Ministry of Health receives until the nineteenth registration for patients interested in sharing their experience with the use of LIRAGLUTIDE (Saxenda) and Smaglutida (Wegovy, OZEPIC). The procedure is part of the analysis process to integrate medications into the treatment of obesity into the uniform health system (SUS).
LIRAGLTE evaluation request from the Brazilian Association for the Study of obesity and metabolic syndrome (ABSO), with the support of the Brazilian Association of Endocrine and metabolism (SBM) and the Brazilian Diabetes Association (SBD).
The document calls for integration to take care of obesity, type 2 diabetes and cardiovascular disease – and patients with this profile that the National Committee for Technologies Integration into the Unified Health System wants to hear it. See how you participate here.
“In the general call, patients are applying to give their certificates and talk about their experience with the medicine,” says Maria Edna de Milo, the Coordinator of the Da`wah Committee in Absu and SPEM.
See more
The endocrinologist explains that the requests need to be taken into account the government’s account of potential foundation. In this sense, the broader proposal that included people with obesity and type 2 diabetes, without heart problems, for example, will generate a significant increase in costs.
He says: “We ended up asking for that patient, who will benefit more than more serious,” he says. By estimating the entities, the annual expenses of each patient will be using Liraglutide $ 7,390.
The price was exactly one of the factors of rejecting the previous demand, which was submitted by the new pharmacist Nordisk, the manufacturer of Liraglutado. At that time, the attempt was to provide the drug to patients with BMI (BMI) above 35 kg/square meters, before diabetes and high risk of cardiovascular disease, a group estimated at 4,026,120 people in five years.
Semagluvertic analysis
Novo Nordisk was the one who submitted the Semaglutida evaluation request, which is an active ingredient of OzemPIC and Wegovy, by Con strite.
In the request, submitted in December 2024, the company suggests the inclusion of patients with second or third -degree obesity (a larger body mass index or equal to 35 kg/m²), without diabetes, between the ages of 45 years and with applicable cardiovascular disease (infarction, stroke, or previous sectarian artery disease).
People with this profile who have benefited from the drug can apply for the General Ministry’s call NSTE link.
After the public invitation with the participation of patients, CONITEC produces a preliminary report indicating whether or not the medication should be recommended. After that, a general consultation is that health professionals, researchers, manufacturers and other patients can make, among other things, their contributions. Then the final report is formulated, submitted for voting, and the decision is revealed. Maria Edna says the expectations are that Contec announces the final evaluation in the first half.
“Today we have five obesity drugs that Anvisa agreed to, none of them in SUS,” says the endocrinologist.
propaganda
“These patients who have already been subjected to messages have a clot and they need to lose weight to improve their health and the quality of life and reduce the risk of new events,” he says. “Providing (treatment) is to provide sufficient service to the population, it’s respect.”
Obesity
Earlier this year, scientists are gathered by the specified diabetes and endocrine disease when excessive fat in the body is a disease. For this, they presented two concepts: clinical obesity and pre -clinical obesity.
The first refers to patients who represent a chronic disease and a system. Indeed, there is a healthy health in general, but the image is a risk factor to develop clinical obesity and diseases such as type 2 diabetes.
To identify groups, which suit patients, the researchers have identified 18 marks and symptoms (13 children and adolescents), and expanding aspects observed after traditional measures, which are weight and body mass index.
However, this index is still widely used and was the basis for the latest obesity survey in the world, the Atlas of Obesity 2025, issued by the World obesity union, WOF.
According to the document, three out of ten Brazilians live with obesity. In 2030, 119.16 million Brazilian people will receive a body mass index, 33.4 % of men and 46.2 % of women will live in obesity if effective measures are not adopted to prevent the development of the disease.
